Role of serum cytokine profile in ulcerative colitis assessment

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1864-1871

  Rodríguez Perlvárez, Manuel Luis ^a   García Sánchez, Valle ^a   Villar Pastor, Carlos Manuel ^a   González, Raál ^a   Iglesias Flores, Eva ^a   Muntane, Jordi ^a   Gõmez Camacho, Federico ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

cytokine profile; disease activity; serum biomarker; ulcerative colitis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; ENDOSCOPY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; CYTOKINES; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; MALE; PROGNOSIS; RISK FACTORS;

EID: 84866365753     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22865     Document Type: Article

References (23)

1. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010; 6: 338-346.
2. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011; 9: 483-489.
3. Matsuda R, Koide T, Tokor C, et al. Quantitative cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis. 2009; 15: 328-334.
4. Raddatz D, Bockemül M, Ramadori G,. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005; 17: 547-557. (Pubitemid 40592713)
5. Zahn A, Giese T, Kerner M, et al. Transcript levels of cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis. BMC Gastroenterol. 2009; 9: 13.
6. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003; 52: 65-70. (Pubitemid 36020767)
7. Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007; 42: 1312-1320. (Pubitemid 47537070)
8. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K,. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis. 2005; 11: 589-596. (Pubitemid 40826347)
9. García-Sánchez V, González R, Iglesias-Flores E, et al. Can systemic cytokines predict relapse of inflammatory bowel disease? Hepatogastroenterology. 2010; 57: 524-530.
10. Alex P, Zachos N, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009; 15: 341-352.
11. Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992; 87: 971-976.
12. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4-β7 integrin. N Engl J Med. 2005; 352: 2499-2507. (Pubitemid 41007865)
13. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000; 47: 404-409.
14. Melgar S, Yeung MM, Bas A, et al. Overexpression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 2003; 134: 127-137. (Pubitemid 37186598)
15. Lieberman BY, Fiocchi C, Youngman KR, et al. Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease. Dig Dis Sci. 1988; 33: 1297-1304.
16. Yasushi U, Masatoshi K, Ryosuke N, et al. Serum proinflamatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology. 2006; 53: 879-882.
17. Liu Z, Yadav PK, Su J, et al. Potential role of Th17 in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009; 15: 5784-5788.
18. Manzano L, Alvarez-Mon M, Vargas JA, et al. Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients. Gut. 1994; 35: 955-960. (Pubitemid 24202727)
19. Veny M, Esteller M, Ricart E, et al. Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther. 2009; 31: 561-572.
20. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57: 1518-1523.
21. Hassan C, Ierardi E, Burattini O, et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis. 2007; 39: 811-817. (Pubitemid 47215583)
22. Yamamoto T, Saniabadi AR, Umegae S, et al. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis. 2006; 12: 719-726. (Pubitemid 44253756)
23. Creed TJ, Lee RW, Newcomb PV, et al. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol. 2009; 183: 164-171.